Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
Medical & technical
Filter frequently asked questions by topic or search the database for specific keywords
Which test is the most comprehensive test?
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by […]
Which cancer cells do you test in an RGCC test?
In any tumour there are several subpopulations of cancer cells, but we only harvest and analyse cells with the tumour-initiating properties.
How are the Onconomics Plus and ChemoSNiP tests different?
The Onconomics Plus test provides information about the sensitivity or resistance of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The ChemoSNiP test can be used to predict whether a patient will respond to drugs and metabolise them properly.
In which countries are RGCC tests approved for use?
Analysis assays cannot be approved. The only test that is approved by the US Food and Drug Administration and the European Medicines Agency is the Cellsearch test. The way we analyse circulating tumour cells is certified for accuracy.
Are your testing methods accredited internationally?
Our methods are accredited by the International Organisation for Standardisation (ISO). Details of our certification can be found on our website.
What’s the scientific evidence for the tests RGCC provide?
You can find the data we have published and presented at medical conferences here.
I only have a blood sample. Is it still possible to order a test that requires both blood and tissue samples?
This depends on the cancer. With the exception of the Oncotrace test, every RGCC test can be conducted with just a blood sample. Certain cancers – for example, glioblastoma and other types of brain cancer – require both a blood and a tissue sample for tests.
How many types of cancer are tested when RGCC says “all types of cancer”?
These tests are for all solid and blood tumour malignancies, with the exception of primary tumours of the central nervous system.
Is it possible to test for circulating tumour cells in a tissue sample?
We calculate the number of circulating tumour cells from the total amount of blood cells, expressed as the volume of circulating tumour cells per millilitre of blood. This cannot be calculated from a tissue sample. To conduct a circulating tumour cell test, a blood sample must be provided.
Why is the circulating tumour cell count not indicated in tissue samples?
The tissue sample taken from the tumour during a biopsy is part of the tumour contain cancerous cells, so there is no need to search for CTC populations.
Can a circulating tumour cell test be carried out during chemotherapy?
Yes, but a patient must wait seven days after chemotherapy treatment before taking the test.
